Quoin Pharmaceuticals Ltd.
QNRX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001671502
In the last 90 days, Quoin Pharmaceuticals Ltd. insiders filed 4 open-market purchases and 0 sales; 19 institutions reported holding it in 13F filings for Q2 2026, worth $6.29M in total; no superinvestor holds it.
13F holders, Q4 2024
Institutional positions in Quoin Pharmaceuticals Ltd. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 14
- +8 vs. Q3 2024
- Shares held
- 1.55M
- +1.41M (+1,004.9%) vs. Q3 2024
- Total value
- $1.01M
- +$936.4K (+1,340.6%) vs. Q3 2024
- New holders
- 10
- 3 more added
- Sold out
- 2
- 1 more reduced
1 institution that held it in Q3 2024 haven't filed for Q4 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting QNRX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 19 | $6.29M |
| Q1 2026 | 21 | $7.82M |
| Q4 2025 | 18 | $12.2M |
| Q3 2025 | 4 | $10.7K |
| Q2 2025 | 6 | $23.4K |
| Q1 2025 | 10 | $90.2K |
| Q4 2024 | 14 | $1.01M |
| Q3 2024 | 7 | $82.2K |
| Q2 2024 | 10 | $127.7K |
| Q1 2024 | 8 | $183.2K |
| Q4 2023 | 3 | $105.6K |
| Q3 2023 | 3 | $7.21K |
| Q2 2023 | 2 | $24.0K |
| Q1 2023 | 4 | $81.1K |
| Q4 2022 | 4 | $52.0K |
| Q3 2022 | 7 | $272.0K |
| Q2 2022 | 8 | $321.0K |
| Q1 2022 | 6 | $419.0K |
| Q4 2021 | 7 | $383.0K |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Quoin Pharmaceuticals Ltd.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Armistice Capital, LLC | 530,000 | $344.9K | 0.01% | +530,000 | New |
| Altium Capital Management LP | 282,249 | $183.7K | 0.06% | +282,249 | New |
| Ikarian Capital, LLC | 275,000 | $178.9K | 0.05% | +275,000 | New |
| Renaissance Technologies LLC | 133,122 | $86.6K | 0.00% | +94,431+244.1% | Added |
| Boothbay Fund Management, LLC | 80,712 | $52.5K | 0.00% | +80,712 | New |
| Apollon Wealth Management, LLC | 80,025 | $52.1K | 0.00% | +80,025 | New |
| Two Sigma Securities, LLC | 52,526 | $34.2K | 0.01% | +20,672+64.9% | Added |
| XTX Topco Ltd | 31,047 | $20.2K | 0.00% | +31,047 | New |
| HRT Financial LP | 27,714 | $18.0K | 0.00% | +27,714 | New |
| Raymond James Financial Inc | 25,119 | $16.3K | 0.00% | +25,119 | New |
| Rhumbline Advisers | 24,126 | $15.7K | 0.00% | +3,340+16.1% | Added |
| UBS Group AG | 4,773 | $3.11K | 0.00% | −18,048−79.1% | Reduced |
| SBI Securities Co., Ltd. | 24 | $16 | 0.00% | +24 | New |
| Raiffeisen Bank International AG | 17 | $11 | 0.00% | +17 | New |
| Virtu Financial LLC | 0 | $0 | 0.00% | −25,165−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −645−100.0% | Sold out |
| Raymond James Financial Services Advisors, Inc. | – | – | – | – | Not filed |